The Cancer Behind Chronic Indigestion: H. pylori, Atrophic Gastritis, and Stomach Cancer Risk

This is not a reason to panic. The great majority of people with ongoing indigestion have no cancer and never will, and most people carrying the bacterium never develop anything serious either. What follows is the small, specific path where indigestion is worth taking seriously, and the plain steps that catch it early.

Why most indigestion is not cancer

Start with the reassurance, because it is well earned. Persistent indigestion, what clinicians call dyspepsia, is overwhelmingly a functional problem: the stomach is uncomfortable, but nothing structurally dangerous is there. In studies of people investigated for dyspepsia, roughly two thirds turn out to have functional dyspepsia with no organic disease, and cancer is an uncommon finding overall, with gastric cancer detected in well under 1% of endoscopies done for dyspepsia.

So the base rate is squarely on your side. If your indigestion is your only symptom, statistically it is far more likely to be functional than anything sinister. The reason to keep reading is not that the odds are frightening. It is that the small subset who do have a treatable, cancer-linked cause tend to look exactly like everyone else at first, which is why the driver gets missed rather than found.

What H. pylori is and why it matters

Helicobacter pylori is a spiral-shaped bacterium that colonizes the stomach lining, often acquired in childhood and then carried silently for decades. It infects a large share of the world's population. In most carriers it causes a low-grade, symptomless inflammation. In some it produces the burning and fullness of dyspepsia, and in a smaller group it sets off a slower, more consequential process.

The consequence is what earns H. pylori its status. The International Agency for Research on Cancer classified it as a Group 1 carcinogen in 1994, meaning the evidence that it causes cancer in humans is definitive, placing it in the same category as tobacco. It is the single strongest known risk factor for stomach cancer, and for most cases of gastric cancer it is the cause of the underlying gastritis. The bacterium does not become cancer. It creates the conditions in which cancer can slowly develop, and that distinction is the whole point of catching it.

The Correa cascade: how the lining changes step by step

Stomach cancer of the common (intestinal) type does not appear out of nowhere. It arrives through a sequence pathologists have mapped closely, named the Correa cascade after the researcher who described it. Chronic H. pylori inflammation comes first. Over years it can progress to atrophic gastritis, where the normal glands of the stomach lining thin out and are lost. From there the lining can shift into intestinal metaplasia, cells that resemble intestine rather than stomach, and then into dysplasia, cells that look genuinely abnormal, before a small fraction reach adenocarcinoma.

Two things make this cascade the center of the story. First, it is slow, unfolding over decades, which leaves a long window to intervene. Second, each step is something a pathologist can actually see on a biopsy, so the process is not invisible once someone looks. That is also the honest reassurance: only a small proportion of infected people, on the order of 1% to 3% in published cohorts, ever travel the whole way to cancer. The cascade is a risk ladder, not a conveyor belt. The aim is to interrupt it early, ideally at the infection itself, long before the lining has changed.

Testing and eradication: the part you can act on

Here is where indigestion stops being purely reassuring and becomes something you can do something about. H. pylori is testable without surgery and treatable with a course of antibiotics, and clearing it changes the trajectory. Under American College of Gastroenterology guidance, a person under 60 with dyspepsia and no alarm features should be tested noninvasively for H. pylori, with the urea breath test or the stool antigen test as the preferred options because both detect active infection rather than just past exposure. If the test is positive, the infection is eradicated, and a follow-up breath or stool test at least four weeks after treatment confirms it is actually gone.

Eradication is not a token gesture. Pooled trial and cohort data show that clearing H. pylori meaningfully lowers future gastric cancer risk, with meta-analyses reporting roughly a third fewer cancers in treated people compared with untreated. The earlier in the cascade you clear it, the more benefit there is, and guidelines now specifically recommend testing and treating people already found to have atrophic gastritis or intestinal metaplasia, because they carry more risk to remove. This is the treatable driver behind "just indigestion" that too often goes unlooked-for: a curable infection sitting under a symptom everyone dismisses.

The alarm features that change the plan

Test-and-treat is the right first move only when the picture is low risk. Certain features flip the plan toward looking directly with a camera. The American College of Gastroenterology advises upper endoscopy rather than noninvasive testing when someone has alarm features: unintentional weight loss, gastrointestinal bleeding or unexplained iron-deficiency anemia, difficulty or pain swallowing, persistent vomiting, or a new onset of dyspepsia at age 60 or older. Any of these raises the chance that something structural, including cancer, is present, and endoscopy both finds it and lets a pathologist biopsy the lining directly.

The logic is proportionate. Most people never cross these lines and are well served by a simple breath or stool test. But the alarm features exist precisely because the base-rate reassurance can lull a genuinely high-risk case into being treated as routine. Knowing which signs earn a closer look is how you get the reassurance when it is warranted and the scope when it is not. If you want to understand the broader habit of not stopping at a comfortable label, the root-cause workup behind IBS applies the same discipline to another symptom that is usually, but not always, benign.

How Healz finds the driver under the label

An indigestion workup is not one lab value. It is your symptom history, your risk factors, an H. pylori result, and, if it comes to it, an endoscopy and a biopsy that only mean something when they are read together. Healz is equipped with root-cause technology, so it does not accept "just indigestion" as the answer. It asks the questions a rushed visit skips, cross-checks your case against 1M+ rare cases, and drills past the symptom to the treatable cause underneath, which for stomach risk is so often the infection nobody tested for.

The rest of the case sits in the same place. Healz has memory that holds every result you upload, your prior H. pylori tests, your endoscopy notes, your biopsy findings, and connects them over time so a drift from gastritis toward atrophic gastritis reads as a trend rather than a lone number lost between appointments. Frontier AI reads the actual documents, so uploading a stomach biopsy gives you a pathology report ai that puts the histology, your symptoms, and your risk factors in one chat instead of ten apps. For anyone weighing a worrying finding, that is what an ai for cancer second opinion looks like in practice: the whole record read at once, not a fresh partial reading each visit. When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.